In contrast, the increased expression of RANKL by tumor cells and tumor-mediated increase of RANKL/OPG ratio in bone microenvironment may be observed in myelomas and in osteolytic metastasis in prostate and breast cancer [27,29,30,31,32,33]. The gene discussed is TNFRSF11B; the disease is plasma cell myeloma.